Login / Signup

The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.

Byungho LimDabin YooYounghwa ChunAreum GoKyung-Jin ChoDaeun ChoiMyoung Eun JungHa Young LeeRebecca J BoohakerJin Soo LeeDooYoung JungGildon Choi
Published in: Blood cancer journal (2022)
Keyphrases
  • combination therapy
  • open label
  • chronic lymphocytic leukemia
  • cell therapy
  • clinical trial
  • stem cells
  • mesenchymal stem cells
  • bone marrow
  • double blind